People · Operator
Named in public records as an officer, director or promoter · active 2012–2022 · Pharmaceuticals, Biotechnology, Mining & Resources
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Moderna LLC | — | Pharmaceuticals | Growth/Late | $691.1M | $16.2B | 2013 |
| Lysosomal Therapeutics, Inc. | — | Biotechnology | Series B | $38.0M | $39.7M | 2014 |
| Good Start Genetics, Inc. | — | Biotechnology | Series B | $28.2M | $396.9M | 2012 |
| Hydra Biosciences Inc | — | Biotechnology | Series A | $10.5M | $379.9M | 2015 |
| Ethos Gold Corp. | — | Mining & Resources | Seed | $5.2M | $2.9M | 2022 |
Robert Carpenter at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert Carpenter on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven E. Hall | 2 | 4 |
| Henri Termeer | 2 | 3 |
| Robert Langer | 1 | 36 |
| Carl Gordon | 1 | 24 |
| Michael Murphy | 1 | 21 |
| Robert Scott | 1 | 20 |
| Bruce Booth | 1 | 12 |
| Clay Thorp | 1 | 10 |
| Scott Kelly | 1 | 9 |
| Noubar Afeyan | 1 | 9 |
| Gary Kurtzman | 1 | 8 |
| Lutz Giebel | 1 | 6 |
| Hendrik Van Alphen | 1 | 6 |
| Daniel Geffken | 1 | 6 |
| Jean George | 1 | 6 |
| Lee Babiss | 1 | 5 |
| Lorence Kim | 1 | 5 |
| Stephane Bancel | 1 | 4 |
| PETER HUTT | 1 | 4 |
| BERNARD DAVITIAN | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.